Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 400

1.

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab.

Puzzoni M, Demurtas L, Giampieri R, Ziranu P, Pusceddu V, Mandolesi A, Cremolini C, Masi G, Gelsomino F, Antoniotti C, Loretelli C, Meriggi F, Zaniboni A, Falcone A, Cascinu S, Scartozzi M.

Ann Oncol. 2017 Oct;28 Suppl 6:vi9-vi10. doi: 10.1093/annonc/mdx422.021. No abstract available.

PMID:
31962869
2.

Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO.

Santini D, Cremolini C, Salvatore L, Lonardi S, Dell'Aquila E, Cattaneo M, Loupakis F, Rossini D, Vincenzi B, Ziampiri S, Buoro V, Tamburini E, Basile D, Corsi DC, Fioroni I, Masi G, Borelli B, Del Re M, Tonini G, Falcone A.

Ann Oncol. 2017 Oct;28 Suppl 6:vi9. doi: 10.1093/annonc/mdx422.019. No abstract available.

PMID:
31962868
3.

Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.

Marmorino F, Cremolini C, Pietrantonio F, Pellegrinelli A, Zucchelli G, Loupakis F, Lonardi S, Aprile G, Morano F, Prisciandaro M, Masi G, Mennitto A, Bergamo F, Cardellino GG, Fassan M, Casagrande M, Milione M, Fontanini G, de Braud F, Falcone A.

Ann Oncol. 2017 Oct;28 Suppl 6:vi6. doi: 10.1093/annonc/mdx422.008. No abstract available.

PMID:
31962766
4.

Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).

Antoniotti C, Marmorino F, Pennati M, Zaffaroni N, Rossini D, Borelli B, Zucchelli G, Moretto R, Pietrantonio F, Masi G, Vannini F, Colombo C, Saettini A, Gini S, Delliponti L, Pfanner E, Brunetti I, Falcone A, Cremolini C.

Ann Oncol. 2017 Oct;28 Suppl 6:vi4. doi: 10.1093/annonc/mdx422.004. No abstract available.

PMID:
31962698
5.

Effects of a universal prevention program on externalizing behaviors: Exploring the generalizability of findings across school and home settings.

Muratori P, Bertacchi I, Masi G, Milone A, Nocentini A, Powell NP, Lochman JE, Jones S, Kassing F, Romero D.

J Sch Psychol. 2019 Dec;77:13-23. doi: 10.1016/j.jsp.2019.09.002. Epub 2019 Nov 20.

PMID:
31837722
6.

Sleep in adults with Autism Spectrum Disorder: a systematic review and meta-analysis of subjective and objective studies.

Morgan B, Nageye F, Masi G, Cortese S.

Sleep Med. 2019 Aug 2;65:113-120. doi: 10.1016/j.sleep.2019.07.019. [Epub ahead of print]

PMID:
31739229
7.

Effect of two exogenous plant growth regulators on the color and quality parameters of seedless table grape berries.

Crupi P, Alba V, Masi G, Caputo AR, Tarricone L.

Food Res Int. 2019 Dec;126:108667. doi: 10.1016/j.foodres.2019.108667. Epub 2019 Sep 11.

PMID:
31732072
8.

Modelling Neurotropic Flavivirus Infection in Human Induced Pluripotent Stem Cell-Derived Systems.

Desole G, Sinigaglia A, Riccetti S, Masi G, Pacenti M, Trevisan M, Barzon L.

Int J Mol Sci. 2019 Oct 30;20(21). pii: E5404. doi: 10.3390/ijms20215404.

9.

Recommendations for the pharmacological management of irritability and aggression in conduct disorder patients.

Pisano S, Masi G.

Expert Opin Pharmacother. 2020 Jan;21(1):5-7. doi: 10.1080/14656566.2019.1685498. Epub 2019 Oct 30. No abstract available.

PMID:
31663786
10.

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.

Marmorino F, Rossini D, Lonardi S, Moretto R, Zucchelli G, Aprile G, Dell'Aquila E, Ratti M, Bergamo F, Masi G, Urbano F, Ronzoni M, Libertini M, Borelli B, Randon G, Buonadonna A, Allegrini G, Pella N, Ricci V, Boccaccino A, Latiano TP, Cordio S, Passardi A, Tamburini E, Boni L, Falcone A, Cremolini C.

Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

PMID:
31573612
11.

Long-Term Outcomes of Parathyroidectomy in Hyperparathyroidism-Jaw Tumor Syndrome: Analysis of Five Families with CDC73 Mutations.

Iacobone M, Camozzi V, Mian C, Pennelli G, Pagetta C, Casal Ide E, Masi G, Zovato S, Torresan F.

World J Surg. 2020 Feb;44(2):508-516. doi: 10.1007/s00268-019-05156-y.

PMID:
31493194
12.

A Comparison of Patients from Argentina and Germany to Assess Factors Impacting Brachial Plexus and Brain Injury.

Socolovsky M, Antoniadis G, Lovaglio A, Durner G, Bonilla G, Schmidhammer M, di Masi G.

J Brachial Plex Peripher Nerve Inj. 2019 Aug 13;14(1):e39-e46. doi: 10.1055/s-0039-1693687. eCollection 2019 Jan.

13.

Sympathetic arousal in children with oppositional defiant disorder and its relation to emotional dysregulation.

Tonacci A, Billeci L, Calderoni S, Levantini V, Masi G, Milone A, Pisano S, Muratori P.

J Affect Disord. 2019 Oct 1;257:207-213. doi: 10.1016/j.jad.2019.07.046. Epub 2019 Jul 5.

PMID:
31301625
14.

Paraneoplastic neurological syndromes.

Iorio R, Spagni G, Masi G.

Semin Diagn Pathol. 2019 Jul;36(4):279-292. doi: 10.1053/j.semdp.2019.06.005. Epub 2019 Jun 21. Review.

PMID:
31253539
15.

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.

Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, Pietrantonio F.

ESMO Open. 2019 May 9;4(2):e000496. doi: 10.1136/esmoopen-2019-000496. eCollection 2019.

16.

Nine syndrome.

Giuffrè GM, Iorio R, Masi G, Frisullo G, Luigetti M.

Acta Neurol Belg. 2019 Sep;119(3):475-476. doi: 10.1007/s13760-019-01151-1. Epub 2019 May 17. No abstract available.

PMID:
31102181
17.

Empathy in Youths with Conduct Disorder and Callous-Unemotional Traits.

Milone A, Cerniglia L, Cristofani C, Inguaggiato E, Levantini V, Masi G, Paciello M, Simone F, Muratori P.

Neural Plast. 2019 Apr 11;2019:9638973. doi: 10.1155/2019/9638973. eCollection 2019.

18.

New Frontiers of Corneal Gene Therapy.

Di Iorio E, Barbaro V, Alvisi G, Trevisan M, Ferrari S, Masi G, Nespeca P, Ghassabian H, Ponzin D, Palù G.

Hum Gene Ther. 2019 Aug;30(8):923-945. doi: 10.1089/hum.2019.026. Epub 2019 May 30.

PMID:
31020856
19.

Acute cerebellar stroke and middle cerebral artery stroke exert distinctive modifications on functional cortical connectivity: A comparative study via EEG graph theory.

Vecchio F, Caliandro P, Reale G, Miraglia F, Piludu F, Masi G, Iacovelli C, Simbolotti C, Padua L, Leone E, Alù F, Colosimo C, Rossini PM.

Clin Neurophysiol. 2019 Jun;130(6):997-1007. doi: 10.1016/j.clinph.2019.03.017. Epub 2019 Apr 6.

PMID:
31005052
20.

Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.

Di Desidero T, Orlandi P, Fioravanti A, Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F, Antoniotti C, Masi G, Fontanini G, Falcone A, Bocci G.

Biochem Pharmacol. 2019 Jun;164:94-105. doi: 10.1016/j.bcp.2019.04.001. Epub 2019 Apr 3.

PMID:
30953637
21.

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.

Moretto R, Morano F, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, de Braud F, Falcone A, Cremolini C.

Clin Colorectal Cancer. 2019 Jun;18(2):116-124. doi: 10.1016/j.clcc.2019.02.007. Epub 2019 Mar 7.

PMID:
30952563
22.

Inflammatory Cytokines in Children and Adolescents with Depressive Disorders: A Systematic Review and Meta-Analysis.

D'Acunto G, Nageye F, Zhang J, Masi G, Cortese S.

J Child Adolesc Psychopharmacol. 2019 Jun;29(5):362-369. doi: 10.1089/cap.2019.0015. Epub 2019 Apr 2.

PMID:
30939048
23.

Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study.

Annunziata P, Masi G, Cioni C, Gastaldi M, Marchioni E, D'amico E, Patti F, Laroni A, Mancardi G, Vitetta F, Sola P.

Neurol Sci. 2019 Jul;40(7):1383-1391. doi: 10.1007/s10072-019-03830-6. Epub 2019 Mar 22.

PMID:
30903415
24.

Effects of melatonin in children with attention-deficit/hyperactivity disorder with sleep disorders after methylphenidate treatment.

Masi G, Fantozzi P, Villafranca A, Tacchi A, Ricci F, Ruglioni L, Inguaggiato E, Pfanner C, Cortese S.

Neuropsychiatr Dis Treat. 2019 Mar 7;15:663-667. doi: 10.2147/NDT.S193891. eCollection 2019.

25.

Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.

Annunziata P, Masi G, Cioni C.

J Neuroimmunol. 2019 May 15;330:130-135. doi: 10.1016/j.jneuroim.2019.03.005. Epub 2019 Mar 8.

PMID:
30878695
26.

Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience.

Guadagni S, Furbetta N, Di Franco G, Palmeri M, Gianardi D, Bianchini M, Guadagnucci M, Pollina L, Masi G, Cremolini C, Falcone A, Mosca F, Di Candio G, Morelli L.

J Minim Access Surg. 2019 Feb 18. doi: 10.4103/jmas.JMAS_265_18. [Epub ahead of print]

27.

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.

Masi G, Vivaldi C, Fornaro L, Lonardi S, Buccianti P, Sainato A, Marcucci L, Martignetti A, Luca Urso ED, Castagna M, Fontanini G, Bergamo F, Musettini G, Urbani L, Sensi E, Balestri R, Montrone S, Pasqualetti F, Cremolini C, Di Paolo A, Zagonel V, Falcone A.

Eur J Cancer. 2019 Mar;110:32-41. doi: 10.1016/j.ejca.2019.01.006. Epub 2019 Feb 7.

PMID:
30739838
28.

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.

Cremolini C, Marmorino F, Bergamo F, Aprile G, Salvatore L, Masi G, Dell'Aquila E, Antoniotti C, Murgioni S, Allegrini G, Borelli B, Gemma D, Casagrande M, Granetto C, Delfanti S, Di Donato S, Schirripa M, Sensi E, Tonini G, Lonardi S, Fontanini G, Boni L, Falcone A.

Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

PMID:
30735919
29.

Clinical and electroencephalographic correlates of psychiatric features in children with frontal lobe epilepsy.

Ticci C, Luongo T, Valvo G, Ferrari AR, Brovedani P, Masi G, Pellacani S, Sicca F.

Epilepsy Behav. 2019 Mar;92:283-289. doi: 10.1016/j.yebeh.2019.01.008. Epub 2019 Feb 4.

PMID:
30731294
30.

Treatment of neuropathic pain after peripheral nerve and brachial plexus traumatic injury.

Lovaglio AC, Socolovsky M, Di Masi G, Bonilla G.

Neurol India. 2019 Jan-Feb;67(Supplement):S32-S37. doi: 10.4103/0028-3886.250699. Review.

31.

[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]

Masi G, Borelli B.

Recenti Prog Med. 2018 Nov;109(11):15e-19e. doi: 10.1701/3031.30301. Italian.

PMID:
30565582
32.

Six-year outcome for children with ODD or CD treated with the coping power program.

Muratori P, Milone A, Levantini V, Ruglioni L, Lambruschi F, Pisano S, Masi G, Lochman JE.

Psychiatry Res. 2019 Jan;271:454-458. doi: 10.1016/j.psychres.2018.12.018. Epub 2018 Dec 4.

PMID:
30537668
33.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D.

JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080.

34.

Lithium treatment in bipolar adolescents: a follow-up naturalistic study.

Masi G, Milone A, Scrinzi G, Mucci M, Viglione V, Bruni G, Berloffa S, Pisano S.

Neuropsychiatr Dis Treat. 2018 Oct 17;14:2749-2753. doi: 10.2147/NDT.S172654. eCollection 2018.

35.

Human papillomavirus infection is not involved in esophageal verrucous carcinoma.

Cappellesso R, Coati I, Barzon L, Peta E, Masi G, Scarpa M, Lanza C, Michelotto M, Ruol A, Cesaro S, Castoro C, Palù G, Nuovo GJ, Fassan M, Rugge M.

Hum Pathol. 2019 Mar;85:50-57. doi: 10.1016/j.humpath.2018.10.024. Epub 2018 Nov 10.

PMID:
30423307
36.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.

Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.

37.

Fingolimod reduces circulating tight-junction protein levels and in vitro peripheral blood mononuclear cells migration in multiple sclerosis patients.

Annunziata P, Cioni C, Masi G, Tassi M, Marotta G, Severi S.

Sci Rep. 2018 Oct 18;8(1):15371. doi: 10.1038/s41598-018-33672-9.

38.

Optimizing PCR primers targeting the bacterial 16S ribosomal RNA gene.

Sambo F, Finotello F, Lavezzo E, Baruzzo G, Masi G, Peta E, Falda M, Toppo S, Barzon L, Di Camillo B.

BMC Bioinformatics. 2018 Sep 29;19(1):343. doi: 10.1186/s12859-018-2360-6.

39.

Trajectories of callous-unemotional traits from childhood to adolescence in referred youth with a disruptive behavior disorder who received intensive multimodal therapy in childhood.

Masi G, Pisano S, Brovedani P, Maccaferri G, Manfredi A, Milone A, Nocentini A, Polidori L, Ruglioni L, Muratori P.

Neuropsychiatr Dis Treat. 2018 Sep 5;14:2287-2296. doi: 10.2147/NDT.S164032. eCollection 2018.

40.

Narcissistic traits and self-esteem in children: Results from a community and a clinical sample of patients with oppositional defiant disorder.

Muratori P, Milone A, Brovedani P, Levantini V, Melli G, Pisano S, Valente E, Thomaes S, Masi G.

J Affect Disord. 2018 Dec 1;241:275-281. doi: 10.1016/j.jad.2018.08.043. Epub 2018 Aug 13.

PMID:
30142585
41.

Phrenic to musculocutaneous nerve transfer for traumatic brachial plexus injuries: analyzing respiratory effects on elbow flexion control.

Socolovsky M, Malessy M, Bonilla G, Di Masi G, Conti ME, Lovaglio A.

J Neurosurg. 2018 Aug 24;131(1):165-174. doi: 10.3171/2018.4.JNS173248.

PMID:
30141757
42.

Late open conversions after endovascular abdominal aneurysm repair in an urgent setting.

Perini P, Gargiulo M, Silingardi R, Piccinini E, Capelli P, Fontana A, Migliari M, Masi G, Scabini M, Tusini N, Faggioli G, Freyrie A.

J Vasc Surg. 2019 Feb;69(2):423-431. doi: 10.1016/j.jvs.2018.04.055. Epub 2018 Aug 17.

PMID:
30126779
43.

KDM2B in papillomavirus-related cancer.

Peta E, Masi G, Barzon L.

Oncoscience. 2018 Jun 27;5(5-6):159-160. doi: 10.18632/oncoscience.434. eCollection 2018 May. No abstract available.

44.

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.

Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, Falcone A.

ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

45.

Oral Mucosa-Derived Induced Pluripotent Stem Cells from Patients with Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome.

Trevisan M, Alvisi G, Barbaro V, Barzon L, Raffa P, Migliorati A, Desole G, Ruzittu S, Masi G, Di Iorio E, Palù G.

Cell Reprogram. 2018 Aug;20(4):215-224. doi: 10.1089/cell.2017.0064. Epub 2018 Jul 10.

PMID:
29989433
46.

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

PMID:
29873679
47.

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.

Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, Tamburini E, Frassineti GL, Mosconi S, Nichetti F, Murgioni S, Troiani T, Borelli B, Zucchelli G, Dal Maso A, Sforza V, Masi G, Antoniotti C, Di Bartolomeo M, Miceli R, Ciardiello F, Falcone A.

Oncologist. 2018 Oct;23(10):1178-1187. doi: 10.1634/theoncologist.2017-0573. Epub 2018 May 8.

48.

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.

Gardini AC, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M.

Tumori. 2018 Dec;104(6):476-479. doi: 10.5301/tj.5000704. Epub 2018 May 9.

PMID:
29739298
49.

Generation of a transgene-free human induced pluripotent stem cell line (UNIPDi001-A) from oral mucosa epithelial stem cells.

Alvisi G, Trevisan M, Masi G, Canel V, Caenazzo L, Nespeca P, Barzon L, Di Iorio E, Barbaro V, Palù G.

Stem Cell Res. 2018 Apr;28:177-180. doi: 10.1016/j.scr.2018.02.007. Epub 2018 Feb 18.

50.

Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.

Fruschelli M, Capozzoli M, Gelmi MC, Masi G, Annunziata P.

Int Ophthalmol. 2019 Apr;39(4):777-781. doi: 10.1007/s10792-018-0870-x. Epub 2018 Mar 2.

PMID:
29500696

Supplemental Content

Support Center